DaVita (DVA) Q1 2026 Earnings Transcript

DaVita reported Q1 adjusted operating income of $482 million, about $50 million above forecast, with adjusted EPS of $2.87 and free cash flow of $140 million. Management raised full-year adjusted operating income guidance to $2.15 billion-$2.25 billion and EPS to $14.10-$15.20, driven by stronger dialysis volumes, better productivity, and labor efficiencies, while reaffirming a $40 million ACA headwind estimate. The company also repurchased 3 million shares in Q1 plus 2 million more afterward, and leverage remained within target at 3.34x EBITDA.

Analysis

The market is likely underestimating how much of this quarter’s upside is actually durable. The volume raise is more important than the headline EPS beat because it comes from a mix of real operating leverage and adjacent share capture from Fresenius closures; that creates a multi-quarter tailwind that is difficult for competitors to offset quickly. In a fragmented, regulated service business, even low-single-digit treatment gains can compound into outsized EBITDA leverage because the incremental chair utilization flows through a largely fixed cost base.

The more interesting second-order effect is that DaVita is using technology spend as an offensive moat rather than a cost-cutting program. If Schedule Hub and broader data infrastructure reduce administrative burden at the center level, the near-term P&L may look noisy, but the strategic effect is to improve throughput, staffing efficiency, and patient retention at a time when labor remains the binding constraint. That argues the true earnings power is still being underwritten by future operating leverage, not the current run-rate.

The consensus risk is that investors focus too much on the apparent conservatism in free cash flow and RPT guidance. FCF is being deliberately capped by buybacks and higher interest expense, while RPT is likely to decelerate as commercial mix normalizes and ACA visibility improves only gradually; that can mask the stronger core unit economics underneath. The bigger bear case is if mortality and transfer-in volume fade after Q2, but the company has already framed the full-year outlook as a range that absorbs these small variables, which reduces the odds of a near-term guide-down unless utilization deteriorates sharply.

Key Decisions for Investors

• Long DVA vs short a basket of dialysis-adjacent healthcare services names over the next 3-6 months: DaVita has clearer operating leverage from volume and labor efficiency, while peers without share capture or AI-enabled workflow gains should lag on margin expansion.
• Buy DVA calls or call spreads with 3-6 month tenor on any post-earnings consolidation: the setup favors a delayed re-rating as investors digest the durability of volume gains and the potential for second-half operating upside; risk is limited to a normalization in mortality or transfer activity.
• Use any rally in DVA to hedge with a small short against CMS-sensitive managed care/ACA-exposed names if enrollment data weakens: the company’s ACA headwind could prove less severe, which would disproportionately benefit DVA relative to companies with direct ACA mix exposure.
• Monitor BRK.B as a source of supply but not a thesis breaker: Berkshire’s block sale creates technical overhang for DVA, yet the repurchase program and continued leverage capacity make the stock absorbable; weak hands may give a better entry on forced selling.
• Avoid fading the technology spend as a negative margin story; if Schedule Hub gains traction, the right trade is to own DVA into the next 2 quarters of operating reviews, because the market may only price the AI/automation benefit once labor productivity inflects visibly.